Magnetic Resonance (MR) Spectroscopy of Breast Cancer Tissue

This study is currently recruiting participants.

Verified September 2011 by Norwegian University of Science and Technology

Sponsor:

Collaborators:

The Research Council of Norway

The Norwegian Women´s Public Health Association

Information provided by (Responsible Party):

Norwegian University of Science and Technology

ClinicalTrials.gov Identifier:

NCT00184210

First received: September 12, 2005

Last updated: September 1, 2011

Last verified: September 2011

History of Changes

Purpose

Breast cancer tissue is collected from women undergoing scheduled surgery for breast cancer. The tissue specimen are analyzed by MR spectroscopy. After MR, the intact tissue specimen can be analyzed by other methods, as histopathology.

The MR spectral profiles are compared to clinical findings as the patients diagnosis, lymph node status and tumor size.

Condition
Breast Neoplasms

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Cross-Sectional
Official Title:	HR MAS MR Spectroscopy of Breast Cancer Tissue

Resource links provided by NLM:

Genetics Home Reference related topics: breast cancer

MedlinePlus related topics: Breast Cancer Cancer

U.S. FDA Resources

Further study details as provided by Norwegian University of Science and Technology:

Biospecimen Retention: Samples With DNA

tissue

Estimated Enrollment:	1000
Study Start Date:	January 2000
Estimated Study Completion Date:	December 2020
Estimated Primary Completion Date:	December 2015 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

women in surgery for breast cancer

Criteria

Inclusion Criteria:

Palpable breast cancer lesion

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00184210

Contacts

Contact: Beathe Sitter, PhD	+47 73 55 13 53	beathesi@ntnu.no
Contact: Tone F Bathen, PhD	+47 73 86 38 44	tone.bathen@ntnu.no

Locations

Norway
Norwegian University of Technology and Science	Recruiting
Trondheim, Norway, 7491
Contact: Beathe Sitter, PhD +47 73 55 13 53 beathesi@ntnu.no

Sponsors and Collaborators

Norwegian University of Science and Technology

The Research Council of Norway

The Norwegian Women´s Public Health Association

Investigators

Study Chair:

Ingrid S Gribbestad, PhD

Norwegian University of Technology and Science

More Information

Publications:

Sitter B, Sonnewald U, Spraul M, Fjosne HE, Gribbestad IS. High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed. 2002 Aug;15(5):327-37.

Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed. 2006 Feb;19(1):30-40.

Bathen TF, Jensen LR, Sitter B, Fjosne HE, Halgunset J, Axelson DE, Gribbestad IS, Lundgren S. MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res Treat. 2006 Oct 24; [Epub ahead of print]

Sitter B, Bathen TF, Singstad TE, Fjøsne HE, Lundgren S, Halgunset J, Gribbestad IS. Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed. 2010 Jan 25; [Epub ahead of print]

Giskeødegård GF, Grinde MT, Sitter B, Axelson DE, Lundgren S, Fjøsne HE, Dahl S, Gribbestad IS, Bathen TF. Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J Proteome Res. 2010 Feb 5;9(2):972-9.

Responsible Party:	Norwegian University of Science and Technology
ClinicalTrials.gov Identifier:	NCT00184210 History of Changes
Other Study ID Numbers:	154080/I30
Study First Received:	September 12, 2005
Last Updated:	September 1, 2011
Health Authority:	Norway: Norwegian Social Science Data Services

Keywords provided by Norwegian University of Science and Technology:

Magnetic Resonance Spectroscopy

Additional relevant MeSH terms:

Breast Neoplasms
Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on May 21, 2013

To Top